Treatment
Psilocybin clinical trials
We’re tracking 100 recruiting studies that include Psilocybin, each written for real people, not researchers, below.
Recruiting studies
- NCT06786325RecruitingPhase 2
Psilocybin treatment study for opioid use disorder
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Philadelphia, PennsylvaniaAges 18–60 - NCT06796062RecruitingPhase 2
Psilocybin for opioid use disorder
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
Albuquerque, New MexicoAges 18–65 - NCT06801041RecruitingPhase 2
Psilocybin therapy for anxiety or depression in cancer survivors
This trial tests if a single dose of psilocybin, given with therapy, can help cancer survivors who struggle with anxiety or depression. You would travel to MD Anderson for treatment and follow-up, and must stop certain medications beforehand.
Houston, TexasAges 18 years+ - NCT06853912RecruitingPhase 2
Psilocybin therapy for PTSD and alcohol use in veterans and first responders
This trial tests whether psilocybin, given along with psychological support, can help military veterans and first responders who have both PTSD and alcohol use disorder. If you're a veteran or first responder looking to reduce or stop drinking, you may be able to participate.
Seattle, WashingtonAges 21–65 - NCT06899165RecruitingPhase 2
Psilocybin therapy for trauma passed down in families
This trial tests whether psilocybin (a substance that can change how you think and feel) combined with talk therapy can help treat depression or anxiety that may be linked to trauma your parent survived. It is for adults whose parent directly experienced genocide and who currently have depression or an anxiety disorder.
New York, New YorkAges 18 years+ - NCT06899334RecruitingPhase 1
Comparing LSD, psilocybin, and DMT in healthy volunteers
This study compares how three different psychedelic substances affect your state of mind. The goal is to better understand these altered states, which may help develop future treatments.
BaselAges 25 years+ - NCT06899594RecruitingEarly Phase 1
Psilocybin for quitting methamphetamine
This trial tests whether psilocybin (a psychedelic medicine) can help people quit methamphetamine. You'll receive counseling before, during, and after the drug session, and your progress will be followed for several months.
Shreveport, LouisianaAges 25–65 - NCT06989957RecruitingPhase 1
Psilocybin and MDMA therapy for PTSD in veterans
This study tests whether a combination of two investigational drugs, psilocybin and MDMA, can help veterans with post-traumatic stress disorder (PTSD). You would receive the drugs in a controlled setting and be monitored closely.
Baltimore, MarylandAges 21 years+ - NCT07072728RecruitingPhase 2
Psilocybin therapy for anxiety in cancer patients
This trial tests whether psilocybin (a psychedelic drug given with talk therapy) can help people with cancer who have adjustment disorder—a condition where a cancer diagnosis causes severe anxiety or stress. It focuses on reducing anxiety and improving emotional well-being.
Abbotsford, VictoriaAges 18–80 - NCT07079930RecruitingPhase 1
Study on psilocybin and D-serine safety in healthy volunteers
This trial tests whether a combination of psilocybin and D-serine is safe and affects mood and thinking. It's for healthy people who want to help research on psychedelics.
JerusalemAges 25–60 - NCT07169747RecruitingPhase 2
Testing psilocybin with therapy for anorexia nervosa
This trial tests two doses of psilocybin (a psychedelic substance) given with psychological support to young adults with anorexia nervosa who have improved and then relapsed. The goal is to see if it is safe and might help prevent future relapses.
LundAges 16–35 - NCT07183748RecruitingPhase 2
Psilocybin microdosing plus therapy for hard-to-treat depression
This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.
BeershebaAges 18–65 - NCT07216404RecruitingPhase 2
Psilocybin therapy for depression in lung cancer patients
This trial tests whether a psychedelic-assisted therapy can help treat major depression in people with non-small cell lung cancer. If you have moderate to severe depression and are receiving cancer treatment, you may be able to join.
Columbus, OhioAges 18 years+ - NCT06902974RecruitingPhase 2
Psilocybin therapy for PTSD from sexual assault
This trial tests whether psilocybin, a psychedelic drug given in a supportive therapy setting, can help women heal from post-traumatic stress disorder (PTSD) caused by a sexual assault that happened 6 or more months ago. You'll receive the drug during supervised sessions and attend therapy visits to see if it reduces your PTSD symptoms.
Rockville, MarylandAges 18 years+ - NCT07490353RecruitingPhase 1
Can psilocybin help treat loss of pleasure?
This trial tests if psilocybin, a psychedelic substance, can improve the ability to feel pleasure (anhedonia) in people with depression who are not taking antidepressants. It also includes healthy volunteers as a comparison group.
Vienna, State of ViennaAges 18–55 - NCT07506395RecruitingPhase 1
Psilocybin group therapy for PTSD
This study tests if psilocybin-assisted group therapy can help people with moderate to severe PTSD. It is for veterans, first responders, female survivors of sexual violence, or Indigenous individuals.
Albuquerque, New MexicoAges 18–89 - NCT07516405RecruitingPhase 1
Psilocybin Safety Study in Older Adults
This research tests whether psilocybin (a psychoactive compound from certain mushrooms) is safe and well-tolerated in healthy people aged 65–85. Researchers want to understand how older adults respond to this substance and whether it could be useful for future treatments.
San Francisco, CaliforniaAges 65–85 - NCT07565493RecruitingEarly Phase 1
Psilocybin with a serotonin blocker in healthy adults
This early-stage research study tests how psilocybin (a naturally occurring compound from certain mushrooms) works when combined with a medication that blocks a specific serotonin pathway in the brain. Researchers want to understand how these two substances interact in healthy volunteers to inform future psychiatric treatment studies.
Baltimore, MarylandAges 21–60 - NCT06919640Enrolling by invitationPhase 1
Psilocybin and brain implant study
This trial tests whether psilocybin (the active ingredient in magic mushrooms) affects brain activity in people who already have a brain-sensing device implanted. It may help researchers understand how psilocybin works in the brain.
San Francisco, CaliforniaAges 21–75 - NCT06798636RecruitingEarly Phase 1
Psilocybin and mental imagery for young people who self-harm
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with a mental imagery therapy can help reduce self-harm thoughts and behaviors in people ages 16–25. You would receive the drug in a safe clinic setting and complete several therapy sessions and questionnaires over a few weeks.
LondonAges 16–25 - NCT07737990Enrolling by invitation
Psilocybin group therapy for treatment-resistant depression
This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.
Toronto, OntarioAges 18 years+ - NCT03289949RecruitingPhase 1
Study brain effects of a serotonin system drug in adults
This Phase 1 study tests how a serotonin-related drug changes brain activity in healthy adults, using brain imaging (MRI) and other measures. Because it involves a drug that may affect the brain, eligibility is designed to keep the results safe and clear.
CopenhagenAges 18 years+ - NCT06512220RecruitingPhase 2
Psilocybin for treatment-resistant depression brain imaging study
This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.
Toronto, OntarioAges 18–65 - NCT06772753RecruitingPhase 1
Study of Psychedelic Effects in Healthy Adults
This study tests how certain psychoactive substances affect your mind and body. It is looking for healthy volunteers to take part in supervised sessions to explore the effects of these drugs.
Baltimore, MarylandAges 25–55
Common questions
- Are there clinical trials studying Psilocybin?
- Yes. Clin2 currently lists 100 recruiting studies that include Psilocybin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Psilocybin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Psilocybin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Psilocybin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.